Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A DOUBLE-BLIND, RANDOMIZED, CONTROLLED MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF RAMIPRIL MR CAPSULES (PANACEA BIOTEC LTD) IN COMPARISON WITH CARDACE (AVENTIS PHARMA LIMITED INDIA) IN PATIENTS OF MILD TO MODERATE HYPERTENSION.

Trial Profile

A DOUBLE-BLIND, RANDOMIZED, CONTROLLED MULTICENTRE STUDY TO ASSESS THE EFFICACY AND SAFETY OF RAMIPRIL MR CAPSULES (PANACEA BIOTEC LTD) IN COMPARISON WITH CARDACE (AVENTIS PHARMA LIMITED INDIA) IN PATIENTS OF MILD TO MODERATE HYPERTENSION.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ramipril (Primary)
  • Indications Hypertension
  • Focus Therapeutic Use

Most Recent Events

  • 07 Dec 2010 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India record.
  • 27 Nov 2010 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top